Ricky McFaline-Figueroa Lab at NYU (@mcfalinelabnyu.bsky.social)

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort - Nature Communications Glioblastoma is resistant to immune-checkpoint inhibitors. In this study, the authors report the results of an expansion cohort (n = 25) of a randomized testing neoadjuvant plus adjuvant pembrolizumab... https://www.nature.com/articles/s41467-024-54326-7